In the older patient — in this case, age 80 — there is a similar split between the 3 previously discussed carboplatin-based regimens. Interestingly, although 
Dr Wakelee sticks with carboplatin/gemcitabine, 
Dr Ramalingam abandons carboplatin/paclitaxel in favor of carboplatin/nab paclitaxel. His rationale for the switch is 2-fold, citing both the potential for less toxicity and data from the seminal trial showing a substantial survival benefit in favor of nab paclitaxel in patients older than age 70.

Socinski MA et al. Safety and efficacy of weekly nab^®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. Ann Oncol 2013;24(2):314-21. Abstract

Socinski MA et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial. J Clin Oncol 2012;30(17):2055-62. Abstract